3-Fluoro-2-nitrobenzoic acid | CAS:1000339-51-4

We serve 3-Fluoro-2-nitrobenzoic acid CAS:1000339-51-4 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
3-Fluoro-2-nitrobenzoic acid

Chemical Name:3-Fluoro-2-nitrobenzoic acid
CAS.NO:1000339-51-4
Synonyms:3-FLUORO-2-NITROBENZOIC ACID;
Molecular Formula:C7H4FNO4
Molecular Weight:185.10900
 
Physical and Chemical Properties:
Density:1.568;
Boiling point:354.2oC;
Flash point:168oC;
 
Specification:
Appearance:Pale lemon crystalline powder 
Purity(HPLC):≥99.0%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Intermediate for organic synthesis
 



Contact us for information like 3-Fluoro-2-nitrobenzoic acid chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,3-FLUORO-2-NITROBENZOIC ACID physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,3-Fluoro-2-nitrobenzoic acid Use and application,3-Fluoro-2-nitrobenzoic acid technical grade,usp/ep/jp grade.


Related News: Authorities asked citizens not to leave the city unless there are special circumstances.2-methylsulfanylpyrazine manufacturer The upstream industry for the R & D, production and sales of pharmaceutical intermediates is the basic chemical raw material industry, and the downstream industry is the chemical bulk drug and chemical pharmaceutical preparation industry.tert-butyl N-[(3S)-piperidin-3-yl]carbamate supplier The upstream industry for the R & D, production and sales of pharmaceutical intermediates is the basic chemical raw material industry, and the downstream industry is the chemical bulk drug and chemical pharmaceutical preparation industry.4-isothiocyanatobenzonitrile vendor ICIG will also supply materials needed for the manufacture of other treatments in earlier stages of development, including neo-GAA, currently in preclinical development as a potential next-generation Pompe disease therapy.The Company’s first-of-kind approach involves engineering human iPSCs in a one-time genetic modification event and selecting a single engineered iPSC for maintenance as a clonal master iPSC line.